NICE updates methods ahead of 'widespread' use of biosimilars
This article was originally published in SRA
Executive Summary
UK health technology assessment body, the National Institute for Health and Care Excellence, has reviewed and updated its methods for providing guidance and advice on biosimilars in preparation for an expected increase in the number of such products coming onto the market1. Among other things, NICE says biosimilars could be subject either to a technology appraisal (guidance) or to a less prescriptive "evidence summary".